Evidence map›Paper›PMID 26183209›Full record

ReviewCurrent opinion in immunology2015

Engineering humoral immunity as prophylaxis or therapy.

Cailin E Deal, Alejandro B Balazs

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Overcoming Physiological Barriers to Nanoparticle Delivery-Are We There Yet?Frontiers in bioengineering and biotechnology · 2019
    Review
  10. Review
  11. Computational and structural biotechnology journal · 2019
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination.Tropical diseases, travel medicine and vaccines · 2017
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Cailin E DealRagon Institute of MGH, MIT & Harvard, 400 Technology Sq., Cambridge, MA 02139, United States.
Alejandro B BalazsRagon Institute of MGH, MIT & Harvard, 400 Technology Sq., Cambridge, MA 02139, United States. Electronic address: abalazs@mgh.harvard.edu.
Ragon Institute of MGH, MIT and Harvard · US

Funding

Engineering Humoral Immunity to Functionally Cure HIV InfectionDP2DA040254 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2015 to 2015
$2.6M
Development of Vectored ImmunoProphylaxis as a strategy against HIVK22AI102769 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI BALAZS, ALEJANDRO BENJAMIN · 2014 to 2015
$264k
NIAID NIH HHS K22 AI102769NIAID NIH HHS K22AI102769NIDA NIH HHS DP2 DA040254NIDA NIH HHS DP2DA040254
6 · The paper itself

Abstract

purpose of the reviewIn this review, we will discuss the field of engineered humoral immunity with an emphasis on recent work using viral vectors to produce antibodies in vivo. As an alternative to passive transfer of monoclonal antibody protein, a transgene encoding an antibody is delivered to cells via vector transduction, resulting in expression and secretion by the host cell. This review will summarize the evidence in support of this strategy as an alternative to traditional vaccines against infection and as novel therapeutics for a variety of diseases. RECENT

findingsHistorically, humoral immunity has been engineered through vaccination and passive transfer of monoclonal antibodies. However, recent work suggests that vectors can be used to deliver transgenes encoding broadly neutralizing antibodies to non-hematopoietic tissues and can mediate long-term expression that is capable of preventing or treating infectious diseases. The production of engineered monoclonal antibodies allows for precise targeting and elimination of aberrant self-proteins that are characteristic of certain neurodegenerative disease. This approach has also been successfully used to combat cancer and addiction in several animal models. Despite the wide array of expression platforms that have been described, adeno-associated virus vectors have emerged as the frontrunner for rapid clinical translation. SUMMARY: Recent advances in vector-mediated antibody expression have demonstrated the potential for such interventions to prevent infection and treat disease. As such, it offers an alternative to immunogen-based vaccine design and a novel therapeutic intervention by enabling precise manipulation of humoral immunity. Success translating these approaches to patients may enable the development of effective prevention against previously intractable pathogens that evade immunity such as HIV, influenza, malaria or HCV and may also enable new treatment options for neurodegenerative diseases such as Alzheimer's disease.

Indexed as

ImmunotherapyAnimalsAntibodies, NeutralizingGenetic VectorsHumansImmunity, HumoralInfectionsProtein EngineeringTransgenesVaccinesAntibodies, NeutralizingVaccines

Identifiers

PMID26183209
PMCPMC4553141
OpenAlexW910576623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.